A Legacy of Innovation: The Max Noureddine Exit Interview, Part One

December 30, 2010 · Leave a comment

Prateek Peres-da-Silva, an intern at Thought Leader Select and student at the University of North Carolina’s Kenan-Flagler Business School, recently sat down with Dr. Maher “Max” Noureddine, Thought Leader Select’s departing chief scientific officer, to discuss his achievements at the company, as well as his vision for the non-profit he is launching to improve the professional lives of health care providers. Peres-da-Silva is a junior at UNC, double-majoring in business and biochemistry.

Prateek Peres-da-Silva: Good morning, Max. I’d like to hear some of your thoughts on your time at Thought Leader Select. Can you share a little about yourself and your role with the company?

Max Noureddine:  Yes, Prateek. In terms of my training, I am a molecular geneticist with experience in biomedical research. I did my doctoral training in the genetics of cell cycle regulation, and then focused on the molecular genetics of neurodegenerative disorders as well as cancer. I joined Thought Leader Select in the fall of 2007 as the chief scientific officer and director of product development. In collaboration with an outstanding team at the company, I became responsible for the development and execution of the company’s line of competitive services and solutions in the area of key opinion leader assessments and profiling in particular, and in pharmaceutical consulting in general.  As CSO, I am responsible for validating the ... read more »

TAGS:                                               

The Thought Leaders Driving Thought Leader Select: A Blog Series—Dr. Maher Noureddine

April 15, 2010 · 1 comment

Dr. Maher “Max” Noureddine joined Thought Leader Select as its chief scientific officer in 2007, after a two-year stint as a senior research fellow in molecular genetics at the National Institute of Environmental Health Sciences/National Institutes of Health (NIEHS/NIH). Prior to his time at the NIEHS/NIH, Max conducted post-doctoral research in Parkinson’s disease at Duke University Medical Center from 2002-2005.  In 2002, Max earned a PhD in biology from the University of North Carolina at Chapel Hill. During his career, Max has co-authored 13 published research studies and presented his research findings at 13 conferences.

The Thought Leader Select Blog recently sat down to catch up with Max Noureddine and learn about his background and how he makes his professional contribution to the work of Thought Leader Select.

TLS Blog:  Thanks for agreeing to an interview with your busy schedule, Max. Why did you join Thought Leader Select in 2007?

Max:  I was at a critical juncture of my career, finishing up my post-doctoral work at Duke in the field of Parkinson’s disease. Basically, I was weighing up my career alternatives, which normally would mean that someone with my academic and scientific background would head straight into university teaching and research.

I had gotten to know Paul Meade, the founder of the company, since we were both pilots in the Civil Air Patrol together. ... read more »

TAGS:                                         

US Prescription Sales Up in 2009; Top Therapy Areas Reflected in Thought Leader Select Projects

April 8, 2010 · Leave a comment

IMS Health reports a 5.1 percent increase in U.S. prescription sales in 2009. Demand for prescription drugs (new therapies and refills) as well as new treatment options for cancer, thrombosis and atrial fibrillation, and new generic treatment options drove growth in the year immediately preceding. Top therapy areas in 2009 include antipsychotics, lipid regulators, proton pump inhibitors, antidepressants, and anti-neoplastic monoclonal antibodies.

Thought Leader Select is pleased to have helped companies strengthen relationships with key opinion leaders (KOLs) and clinical investigators in 40% of the major therapeutic areas driving industry growth in 2009. Thought Leader Select has identified, profiled, and provided engagement and deployment recommendations for more than 1000 KOLs in the areas of insulin analogs, anti-platelets, GI and inflammatory, seizure disorders, erythropoietins, and anti-arthritic/biologic response modifiers.

Read the full report here.

TAGS: